| Biomarker ID | 1005 |
| PMID | 23071848 |
| Year | 2012 |
| Biomarker | FCRL3 (Fc receptor-like 3)+ SAMSN1 (SAM domain, SH3 domain and nuclear localization signals 1) |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Blood |
| Subjects | Humans |
| Regulation | Downregulated (1.61 fold) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Controls Vs High Grade Prostate Cancer (GS 8 and above) |
| Type of Biomarker | Diagnostic |
| Cohort | In total, 1938 samples including 739 Prostate Cancer (PrCa) cases and 1,199 controls (G0) were collected and further divided. COHORT 1: 245 samples (GS8 = 54, G0 = 191) ; COHORT 2: 182 samples (GS8 n=80 and controls n=102), Independent Test Set, COHORT 3: 121 samples (GS8 n=64 and controls n=57). A Cohort IV group of cases with intermediate grade cancer (G6 n=33, G7(3+4) n = 35, and G7(4+3) n = 43) was used to evaluate cancer aggressiveness performance. |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.69 |
| Accuracy | NA |
| Level Of Significance | p = 0.00000285 |
| Method Used | Initial Discovery: Microarray; Verfication (Cohort 1, 2,3,4): qPCR |
| Clinical | No |
| Remarks | Set of 85 genes were identified from Microarray Hybridisation, then using qPCR Cohort 1 (EDTA samples), Cohort 2 (PaxGene samples). Then 20 genes found using these 2 cohorts were verified on a Malasyian Cohort, and finally 7 genes were selected for the signature. |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |